Viewing Study NCT07058012


Ignite Creation Date: 2025-12-26 @ 10:20 PM
Ignite Modification Date: 2025-12-26 @ 10:20 PM
Study NCT ID: NCT07058012
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-07-10
First Post: 2025-03-06
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
Sponsor: NSABP Foundation Inc
Organization:

Organization Data

Organization:
Class: NETWORK
Study ID: NSABP FC-13
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor:
Lead Sponsor Class: NETWORK
Responsible Party:
Responsible Party Title:
Responsible Party Type: SPONSOR
Responsible Party Affiliation:
Old Name: None
Old Organization: None

Collaborators

Collaborators

Name Class View
None INDUSTRY View